Avasimibe

Avasimibe inhibits ACAT with IC50 of 3.3 μM, also inhibits human P450 isoenzymes CYP2C9, CYP1A2 and CYP2C19 with IC50 of 2.9 μM, 13.9 μM and 26.5 μM, respectively.A cholesterol reducing compound that also inhibits CYP.

InformationAvasimibe (CI-1011, PD-148515) inhibitsACATwithIC50of 3.3 μM, also inhibits human P450 isoenzymes CYP2C9, CYP1A2 and CYP2C19 withIC50of 2.9 μM, 13.9 μM and 26.5 μM, respectively.In vitroAvasimibe at concentration of 1μg/mL causes

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

An orally bioavailable inhibitor of ACAT (IC₅₀s = 24 and 9.2 &microM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid

Gentian Violet 1%, 16oz, ADI

Immunotag™ Mouse Apolipoprotein C-I ELISA Kit

Immunotag™ Mouse Fatty acid-binding protein, adipocyte ELISA Kit

Species : Mouse Assay Principle : Quantitative Target Name : Angiopoietin-related protein 4 Sensitivity : 0.78 pg/ml Detection Range : 6.25 pg/ml-200 pg/ml

MOUSE SLPI / ANTILEUKOPROTEINASE ELISA KIT